- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.04. | Bayer taps new North America marketing chief for consumer health division | ||
| 09.04. | Advanced therapy CDMO Ascend nabs Florida manufacturing site and team from ocular gene therapy outfit Beacon | ||
| 09.04. | As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake | ||
| 09.04. | FDA slams Jubilant Generics, Canada's Contract Pharmaceuticals with Form 483s | ||
| 09.04. | 'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study | ||
| 08.04. | Generic drug makers must close 'knowledge gap' to overcome doctors' brand loyalty: GlobalData | ||
| 08.04. | AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod | ||
| 08.04. | Medtronic survey finds older women face gap in awareness of and screening for aortic stenosis | ||
| 08.04. | FDA swats away Supernus' Parkinson's disease infusion pump for 3rd time | ||
| 08.04. | With wider approval, J&J and Legend's Carvykti quickly leaps ahead of BMS' rival myeloma CAR-T | ||
| 08.04. | Docs sing praises of Madrigal's Rezdiffra, predict rapid uptake | ||
| 05.04. | In refiling $16.5B Catalent buyout pitch, Novo gives FTC more time for review | ||
| 05.04. | Bristol Myers' Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer | ||
| 05.04. | As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid sales model | ||
| 05.04. | AstraZeneca's Imfinzi tackles another type of lung cancer with latest trial win | ||
| 05.04. | House committee to press FDA Commissioner Robert Califf on shortage oversight, other issues | ||
| 05.04. | AbbVie retains ad spending leadership, but some surprise drugs make the top 10 in March | ||
| 05.04. | Novartis finally ready for Pluvicto filing in earlier prostate cancer as patient survival data clear up | ||
| 04.04. | Sanofi pledges to keep polio vaccine supplies afloat in India after new approval | ||
| 04.04. | Bayer honors Trans Day of Visibility by highlighting work to protect LGBTQ+ workers | ||
| 04.04. | Pfizer's Velsipity poised to outpace BMS' Zeposia in ulcerative colitis market, but must head off further competition: analysts | ||
| 04.04. | Sanofi settles 4,000 Zantac state lawsuits, still faces Delaware claims | ||
| 04.04. | Arbutus, Genevant gain an edge in COVID patent scrap with Moderna | ||
| 04.04. | Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience | ||
| 04.04. | Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
